51. Infectious Risks Associated with IL-2R Antagonist [Basiliximab (Simulect) and Daclizumab (Zenapax)]

  1. Deepali Kumar MD, MSc, FRCPC and
  2. Atul Humar MD, MSc, FRCPC
  1. Steven D. Burdette MD, FIDSA

Published Online: 5 MAY 2011

DOI: 10.1002/9781444397949.ch51

The AST Handbook of Transplant Infections

The AST Handbook of Transplant Infections

How to Cite

Burdette, S. D. (2011) Infectious Risks Associated with IL-2R Antagonist [Basiliximab (Simulect) and Daclizumab (Zenapax)], in The AST Handbook of Transplant Infections (eds D. Kumar and A. Humar), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444397949.ch51

Editor Information

  1. Transplant Infectious Diseases, University of Alberta, Edmonton, Canada

Author Information

  1. Infectious Diseases Fellowship, Miami Valley Hospital Transplant Program, WSU Boonshoft School of Medicine, Dayton, OH, USA

Publication History

  1. Published Online: 5 MAY 2011
  2. Published Print: 13 MAY 2011

ISBN Information

Print ISBN: 9780470658277

Online ISBN: 9781444397949

SEARCH

Keywords:

  • infectious risks associated with IL-2R antagonist - [Basiliximab (Simulect) and Daclizumab (Zenapax)];
  • interleukin-2 (IL-2) antagonist saturating IL-2 receptors - preventing T cells from replication;
  • standard BK screening protocols;
  • bacterial infections;
  • fungal infections;
  • HCV/HBV, data mixed - increased risk and no risk of recurrent HCV infection;
  • standard monitoring;
  • EBV/PTLD - standard EBV screening protocols for EBV D+/R–SOT recipients;
  • CMV - no increased risk during induction;
  • BK virus - standard BK screening protocols